Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?

It wasn't so long ago that Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, seemed to be firing on all cylinders. However, the past year has been challenging for the drugmaker.One reason behind its poor performance over the trailing-12-month period is that it has encountered clinical setbacks. CagriSema, an investigational weight loss medicine, performed well in phase 3 studies, but not quite as well as management had promised. Elsewhere, Novo Nordisk's biggest rival in this area, Eli Lilly, has registered significant clinical wins that arguably put it ahead in this fast-growing market.Still, Novo Nordisk hasn't said its last word yet. The company has recently made significant moves to strengthen its anti-obesity pipeline. Should investors buy the stock following these developments?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool